Persistent inflammation underlies many prevalent diseases including atherosclerosis and
diabetes. There is a growing appreciation that inflammation and its active resolution may be
modulated by endogenously produced lipids. Pre-eminent amongst these mediators are
lipoxin [LX] A4 and LXB4. The LXs are eicosanoids and display both anti-inflammatory and
pro-resolving bioactions. In effective host defence lipid mediator biosynthesis is
characterised by a switch from pro-inflammatory prostaglandin and leukotriene (LT) …